Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

• Type of Material: Article
• Authors: Amit G. Singal, University of Texas Southwestern Medical Center; Anjana Pillai, Emory University; Jasmin Tiro, University of Texas Southwestern
• Language: English
• Date: 2014-04-01
• Publisher: Public Library of Science
• Publication Version: Final Published Version
• Copyright Statement: © 2014 Singal et al
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1371/journal.pmed.1001624
• Title of Journal or Parent Work: PLoS Medicine
• ISSN: 1549-1277
• Volume: 11
• Issue: 4
• Start Page: e1001624
• End Page: e1001624
• Grant/Funding Information: This work was conducted with support from UT-STAR, NIH/NCATS Grant Number KL2 TR000453, NIH/NCATS Grant UL1-TR000451, and the ACG Junior Faculty Development Award awarded to AS.
• Keywords: RANDOMIZED CONTROLLED-TRIAL; VIRAL-HEPATITIS; EARLY-DIAGNOSIS; HEPATITIS-C VIRUS; SYSTEMATIC REVIEWS; General & Internal Medicine; ASIAN-AMERICANS; COLORECTAL-CANCER; Science & Technology; Medicine, General & Internal; UNITED-STATES; AMERICAN PATIENTS; LIVER-TRANSPLANT CENTER; MEDICINE, GENERAL & INTERNAL; Life Sciences & Biomedicine
• Research Categories: Health Sciences, General

Abstract

BACKGROUND: Surveillance for hepatocellular carcinoma (HCC) has level I evidence among patients with hepatitis B but only level II evidence in patients with cirrhosis. This lack of randomized data has spurred questions regarding the utility of HCC surveillance in this patient population; however, lack of randomized data does not equate to a lack of data supporting the efficacy of surveillance. The aim of our study was to determine the effect of HCC surveillance on early stage tumor detection, receipt of curative therapy, and overall survival in patients with cirrhosis. METHODS AND FINDINGS: We performed a systematic literature review using Medline from January 1990 through January 2014 and a search of national meeting abstracts from 2009-2012. Two investigators identified studies that reported rates of early stage tumor detection, curative treatment receipt, or survival, stratified by HCC surveillance status, among patients with cirrhosis. Both investigators independently extracted data on patient populations, study methods, and results using standardized forms. Pooled odds ratios, according to HCC surveillance status, were calculated for each outcome using the DerSimonian and Laird method for a random effects model. We identified 47 studies with 15,158 patients, of whom 6,284 (41.4%) had HCC detected by surveillance. HCC surveillance was associated with improved early stage detection (odds ratio [OR] 2.08, 95% CI 1.80-2.37) and curative treatment rates (OR 2.24, 95% CI 1.99-2.52). HCC surveillance was associated with significantly prolonged survival (OR 1.90, 95% CI 1.67-2.17), which remained significant in the subset of studies adjusting for lead-time bias. Limitations of current data included many studies having insufficient duration of follow-up to assess survival and the majority not adjusting for liver function or lead-time bias. CONCLUSIONS: HCC surveillance is associated with significant improvements in early tumor detection, receipt of curative therapy, and overall survival in patients with cirrhosis. Please see later in the article for the Editors' Summary.